SYK and Sepsis: The small molecule PRT062607 inhibits SYK with an anti-SYK activity that is 80-fold greater than its affinity for other kinases, indicating that the molecule may have a better therapeutic window and, hence, may represent a good candidate to investigate the role of SYK in sepsis and other clinical conditions with an activated immune system (35, 36, 52–54).